Sumant’s top pick AGN given lower risk to reimbursement pressures & an underappreciated pipeline. Leverage & CF remain the key focus for investors. Tools/Animal Health (=) — Derik notes more “headline” than “real” risks from policy which will create opportunities for a group growing MSD, although valuations remain a

s top =ick AGN =iven lower risk to reimbursement pressures & an underappreciated =ipeline. =/span>Leverage & CF remain the key focus for investors. Tools/Animal Health ==) — Derik notes more "headline" than =E244oreal" risks from policy which will create opportunities =or a group growing MSD, although valuations re